Oncotarget

Research Papers:

Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells

Seiichi Okabe _, Tetsuzo Tauchi, Yuko Tanaka, Juri Sakuta and Kazuma Ohyashiki

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:53116-53126. https://doi.org/10.18632/oncotarget.10605

Metrics: PDF 1164 views  |   HTML 2410 views  |   ?  


Abstract

Seiichi Okabe1, Tetsuzo Tauchi1, Yuko Tanaka1, Juri Sakuta1, Kazuma Ohyashiki1

1Department of Hematology, Tokyo Medical University, Tokyo, Japan

Correspondence to:

Seiichi Okabe, email: okabe@tokyo-med.ac.jp

Keywords: chronic myeloid leukemia, phosphoinositide 3-kinase, ABL tyrosine kinase inhibitor, feeder cell

Received: May 06, 2016     Accepted: June 30, 2016     Published: July 14, 2016

ABSTRACT

ABL tyrosine kinase inhibitor (TKI) therapy has improved the survival of patients with Philadelphia (Ph) chromosome-positive leukemia. However, ABL TKIs cannot eradicate leukemia stem cells. Therefore, new therapeutic approaches for Ph-positive leukemia are needed. Aberrant activation of phosphoinositide 3-kinase (PI3K) signaling is important for the initiation and maintenance of human cancers. Copanlisib (BAY80-6946) is a potent inhibitor of PI3Kα and PI3K-δ. Here we investigated the efficacy of combination therapy of copanlisib with an ABL TKI (imatinib, nilotinib, or ponatinib) using BCR-ABL-positive cells. Although the effects of the ABL TKI treatment were reduced in the presence of the feeder cell line, HS-5, copanlisib inhibited cell growth. Upon combining ABL TKI and copanlisib, cell growth was reduced. Ponatinib and copanlisib combined therapy reduced tumor volume and increased survival in mouse allograft models, respectively. These results indicate that the PI3Kα and -δ inhibitors overcame the chemoprotective effects of the feeder cells and enhanced ABL TKI cytotoxicity. Thus, co-treatment with ABL TKI and copanlisib may be a powerful strategy against ABL TKI-resistant cells, including those harboring the related T315I mutation.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10605